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The leukocyte function-associated antigen 1 (LFA-1)t molecule belongs to the
integrin family ofadhesion proteins (1, 2). This group contains LFA-1, Mac-1, and
p150,95, which share acommon/3chain, but havedifferentachains (3). Thecommon
# subunit is now designated CD18, whereas the a subunits are designated CDlla
for LFA-1, CD11b for Mac-1, and CDllc for p150,95 (4). Each of these molecules
has a somewhat different cellular distribution amonghematopoieticcells (5). mAbs
to these determinants have been useful in determining that these proteins are in-
volved in interactions ofthe cell with its environment as in cell-cell adhesion, cell-
ligand interactions, orcellular migration and homing (5-7). LFA-1 was first detected
by the recognition ofmAbs that could block CTL-mediated killing(8). The LFA-1
molecule has since been shown to be involved in the adhesion oftarget and effector
cells in NK-mediated killing, the induction ofT cellproliferation by accessorycell-de-
pendent stimuli, andin some Tcell-dependent B cellresponses(5-8). Children with
a genetic deficiency in the surface expression of LFA-1 have diminished cell con-
tact-dependent functional responses (5).
The LFA-1 molecule, therefore, is important in mediating events external to the
cell membrane, but there islittle information about whether perturbation ofLFA-1
may also transmit information to the lymphocyte. Such a possibility cannot be ex-
amined with mixed cell populations, as the anti-LFA-1 mAb may inhibit the final
functional outcome by preventing cell contact. There are circumstances, however,
where theanti-LEA-1 mAb can augmentTcell activation inthe absence ofaccessory
cells. Thus, forexample, the responseofhighly purified Tcells toimmobilized rnAbs
to CD3 was enhanced by coimmobilized mAbs to LFA-1 (9), suggesting the possi-
bility that LFA-1 molecules could transmit signals to the cell. However, the genera-
tion of a positive signal by the anti-LFA-1 mAb could not be distinguished from
increased adherence or stabilization oftheTcell to the surface, thereby permitting
more effective interaction with the anti-CD3 mAb. More recently, purified Tcells
were shown to proliferate modestly in response to the combination ofimmobilized
anti-LFA-1 mAb and PMA (10). This suggested the possibility that the anti-LFA-1
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mAb could provide a costimulatory signal similar to that provided by calcium iono-
phores, which raise intracellular calcium ([Ca2+];) (11). In other studies, however,
soluble anti-LFA-1 mAbs have been reported to modify T cell proliferative responses
to immobilized anti-CD3 mAbs in either a positive or negative manner (12). Thus,
anti-CD11a mAbs were costimulatory whereas anti-CD18 mAbs were inhibitory. These
findings raised the possibility that binding to the a or (3 chains might differentially
affect T cell activation.
We have recently shown enhanced activation of human T cell clones when cells
were pretreated with mAbs that recognized two different surface antigens, including
the combinations ofmAbs to CD3 + HLA-A,B,C, CD3 + CD4/CD8, or HLA-A,B,C
+ CD4/CD8 followed by crosslinking (13). As this experimental system provided
a homogeneous population of cells free of accessory cells, it was possible to use T
cell clones to examine the ability of mAb to LFA-1 to costimulate T cells in the ab-
sence of either accessory cells or an immobilized stimulus. Both the ability to in-
crease [Ca2+]i as a marker of transmembrane signaling and the ability to activate
the cells functionally were examined. The results show that crosslinking anti-LFA-1
mAb alone does not increase [Ca2+]i nor does it stimulate T cells. However, cross-
linking LFA-1 and CD3 simultaneously, but independently, results in a prolonga-
tion of the increase in [Ca2+ ]i and in enhancement of both IL-2 production and
proliferation. The LFA-1 molecule, therefore, can transmit a costimulatory signal
to T lymphocytes that results in enhanced activation when the CD3 complex is also
engaged.
Materials and Methods
mAbs and Reagents.
￿
The mAbs included OKT3 (Ortho Pharmaceutical, Raritan, NJ), an
IgG2a mAb directed to the CD3 complex on mature T cells (14); Leu-4 (Becton Dickinson
Immunocytometry Systems, Mountain View, CA), an IgGl mAb against CD3 ; 158.86 (gift
from Dr. Jefferson Paslay; Upjohn, Kalamazoo, MI), an IgG2b mAb against CD3; W6/32,
(American Type Culture Collection [ATCC], Rockville, MD), an IgG2a mAb directed to
nonpolymorphic class I MHC molecules; MB40.5 (ATCC), an IgG1 mAb directed to non-
polymorphic classI MHC determinants; 60.3 (gift from Dr. Patrick Beatty, Fred Hutchinson
Cancer Center, Seattle, WA), an IgG2a mAb directed to an epitope common to theS chain
(CD18) of LEA-1, Mac-1, and 150,95; TS1/18 (gift of Dr. T. A. Springer, Harvard Medical
School, Boston, MA), an IgGl mAb directed to CD18; TSl/22 (gift of Dr. T. A. Springer,
Harvard Medical School, Boston, MA), an IgGl mAb directed against the a chain of the
LFA-1 molecule (CD11a); and antiTac (gift of Dr. Thomas Waldmann, National Cancer In-
stitute, Bethesda, MD), an mAb against the p55 component of the IL-2-R (CD25). The Fab
fragments of the anti-CD3 mAb 64.1 were the kind gift of Dr. Ellen Vitetta (University of
Texas Southwestern Medical Center, Dallas, TX). Control mAbs included MOPC (ATCC,
IgGl) and P1.17 (ATCC, IgG2a).
Affinty-purified goat anti-mouse Ig used in cultures (GaMIg; Cappel Laboratories, Mal-
vern, PA) was diluted in culture medium to a final concentration of 10 Jig/ml. GaMIg an-
tiserum obtained from Antibodies Inc. (Davis, CA) was also used in some experiments. No
difference was observed in the response elicited by either preparation. Affinity-purified isotype-
specific goat anti-mouse Ig (anti-IgG2a, anti-IgGI, and anti-IgG2b; Fisher Scientific Co.,
Pittsburgh, PA) was used at a final concentration of 10 gg/ml in cultures or at 5 kg/ml in
flow cytometric determinations of [Ca2'];. According to the manufacturer, crossreactivity of
the isotype-specific antibodies was never >3 70. rIL-2 was the gift ofCetus Corp., (Emeryville,
CA). PHA was obtained from Burroughs Wellcome Co., Research Triangle Park, NC.
T Cell Clones.
￿
T cell clones were prepared as previously described (15). Before use, clones
were passed every 7 d for three to four passages by culturing equal numbers of the cloneWACHOLTZ ET AL.
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(3 x 105 cells/well) and irradiated syngeneic or allogeneic PBMC with PHA and IL-2 to
generate sufficient numbers of cells. The cells were then cultured in fresh medium containing
IL-2, but no PHA or feeder cells for 12-19 d. Cells were used during the 12-19-d period be-
cause the cellular responses were stable and reproducible. If maintained longer without re-
stimulation, responsiveness declined. Cells were washed on at least three occasions during
this period and recultured with IL-2 (20 U/ml). No feeder cell contamination could be de-
tected. Data concerning the phenotype and function for some of these clones (NPI, NP7,
NP19, NP18, NP13, LM2, and LM5) have been presented previously (13, 16). All these clones
were >97% CD18 or CD11a positive. Clonality for these cells was demonstrated by analysis
ofthe rearrangement patterns ofthe genes encoding the fl chain ofthe TCR (16). These clones
have also been shown to mediate MHC-unrestricted cytotoxicity and to provide help for B
cell differentiation (15, 16). Clones BR2, BR4, and BRIO were isolated for this study from
a child with leukocyte adhesion deficiency (LAD) and expressed <1% surface CD18 or CD11a.
Clones NP18 and NP13 were CD8' ; all other clones were CD4'.
Reacting T Cells with mAb.
￿
To stimulate clones for both analysis of [Ca2']i and functional
responses, the cells were suspended at 1.5 x 107 cells/ml in cold PBS containing 2vlo FCS.
The cells were incubated with saturating concentrations of the mAb for 30 min at 4°C and
then washed twice. After washing, the cells were resuspended in appropriate medium for
analysis of functional responses.
PhenotypicAnalysis.
￿
Phenotypic analysis of the clones was carried out by staining cellson
ice with saturating concentrations of the mAb listed above. Control cells were stained with
an isotype-matched irrelevant mAb. Cells were washed, and then treated with a secondary
fluorescenn-conjugated GaMIg (CooperBiomedical, Inc., Malvern, PA). The stained clones
were analyzed by flow cytometry using a 50HH flow cytometer (Ortho Diagnostic Systems
Inc., Westwood, MA) as previously described (17, 18). Dead cells were gated out afterincuba-
tion with propidium iodide. Surface expression of these antigens remained constant during
the study period.
Measurement ofPHJThymidine Incorporation.
￿
Cell culture was carried out in medium RPMI
1640 supplemented with 10% FCS, penicillin G (200 U/ml), and r.-glutamine (0.3 mg/ml)
in 96-well flat-bottomed microtiter plates (Costar; Cambridge, MA) in a total volume of 200
p.l. T cell clones previously treated with various mAbs were cultured at 105 cells/well with
or without GaMIg or isotype-specific secondary antibodies (10 ug/ml) for a total of 36 h,
as this was previously determined to give the optimal response. 18 h before harvesting on
glass fiber filter paper, 1 p.Ci of [3H]thymidine (6.7 Ci/mmole; New England Nuclear,
Boston, MA) was added to the culture. [3H]Thymidine incorporation was measured by liquid
scintillation counting. All data are expressed as mean cpm t SEM oftriplicate determinations.
Assayfor IL-2 Production.
￿
T cells pretreated as described above were cultured for 18 h with
or without GaMIg (10 ug/ml) in the presence ofantiTac mAb (2 pg/ml) to prevent absorption
of IL-2. To assess IL-2 content in the supernatants, IL-2-dependent CTLL-2 cells (3.5 x
103 cells/well) were cultured in RPMI 1640 medium containing 1017o FCS with diluted cul-
ture supernatants or different concentrations of IL-2 to define the standard curve. The cells
were incubated for 14 h at 37oC, then pulsed with 1 p.Ci of [3H]thymidine (6.7 Ci/mmole;
New England Nuclear) and harvested 14 h later. [3H]Thymidine incorporation was measured
by liquid scintillation counting. The amount of IL-2 in the culture supernatants was com-
puted by comparison with the standard curve.
Analysis of Cytosolic Free Calcium ([Ca2'f).
￿
Flow cytometry using cells loaded with the
fluorescent calcium-sensitive dye indo-1 was used to analyze changes in [Ca2*]; as previously
described (19). Cells suspended in RPMI 1640 medium containing 5% FCS and 10 mM
Hepes (pH 7.4) at a density of 4-10 x 106 cells/ml were incubated with 5 pM indo-1/AM
(Molecular Probes; Eugene, OR) for 30 min at 37oC. The suspensionwas diluted 1 :10 with
the same medium and incubated an additional 30 min at 37 oC. The cellswere then stained
at VC with the appropriate mAb as described above. Before use, an aliquot of cells was
resuspended in warm HBSS containing 1% human serum and 10 mM Hepes (pH 7.4) to
give a final concentration of 106 cells/ml.
Flow cytometric analysis was done with the 50HH flow cytometer and associated 2150 com-
puter (Ortho Diagnostics Systems Inc.). An argon laser (Coherent Innova 90-5, Coherent434
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Inc ., Palo Alto, CA) focused in the UV (351-368 nm) was used to excite indo-1 . The violet
fluorescent emission, which increases as the dye binds calcium, was selected using aDF 405/20
bandpass filter(Omega Optical, Inc., Brattleboro, VT) after separation with a 430-nm dichroic
mirror (Ortho Diagnostics Systems Inc .). Blue emission, which decreases as calcium is bound,
was selected using aDF 485/22 bandpass filter(Omega Optical, Inc.) . Cells were maintained
at 37 °C, and baseline data were collected for 1.5-2 min before addition of crosslinking anti-
body. A modified version of the "Ratiorg" protocol was used to calculate the violet to blue
ratio, which is proportional to intracellular calcium (20), and to display it as a function of
time . Data were smoothed using the program "Normcon" and the program "Cyto2D" was
used to determine the mean ratio and percentage of responding cells (both provided by Dr.
Peter Rabinovitch through the Naval Medical Research Institute, Bethesda, MD) .
To determine the approximate [Ca2+] ; that corresponds to a measured violet to blue ratio,
indo-l-loaded cells were simultaneously studied in the flow cytometer and in suspension using
a fluorimeter(MPF44B ; Perkin-Elmer Corp ., Pomona,CA) . Ionomycin (Calbiochem-Behring
Corp., San Diego, CA), a calcium ionophore, was used to vary [Ca 2+] ;, which was calculated
for cells in suspension as described by Grynkiewicz et al . (20) . This value was related to the
simultaneously obtained violet-to-blue ratio determined with the flow cytometer to derive
a standard curve.
Results
Crosslinking CD3 with CD18 or CD11a Prolongs the Calcium Signal.
￿
When human
T cell clones are pretreated with an anti-CD3 or an anti-HLA-A,B,C mAb followed
by crosslinking with a secondary GaMIg, two different, but characteristic changes
in [Ca2+ ]i are observed (13, 21) . As shown in Fig . 1, crosslinking CD3 resulted in
a rapid increase in [Ca2+] ; in -90% of cells followed by a rapid decline . Crosslinking
HLA-A,B,C caused a delayed, but more sustained increase in a smaller percentage
FIGURE 1 .
￿
Crosslinking CD3
and CD18 results in a prolonged
increase in [Ca2+ ] ; . Clone NP18
(CD8 +) cells were pretreated
with the indicated mAb (anti-
CD3-OKT3; anti-HLA-A,B,C-
W6/32 ; anti-CD18-60.3) at 4°C .
Cells were warmed to 37°C and
were analyzed by flow cyto-
metry for 1.5-2 min to establish
the baseline [Ca2+]; . At the
arrow, the crosslinking sec-
ondary antibody, GaMIg, was
added and the measurement
continued for up to 8 min . The
data were analyzed in terms of
the percentage ofTcellsthat in-
creased [Cad+ ]i (A and B), and
in terms of the mean fluores-
cence ratio (violet to blue),
which reflects the mean [Ca2+ ] ;
ofthe population (C and D) . In
the absence ofGaMIg, themAb
did not induce an increase in
[Ca 2+]i. GaMIg induced no in-
crease in [Ca2+ ]i in cells stained
with an irrelevant controlmAb
(data not shown) .WACHOLTZ ET AL.
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of cells at any given time point . Crosslinking LFA-1 using the mAb 60.3 (anti-ß
chain, CD18) did not increase [Ca2']j . However, when cells were pretreated with
saturating concentrations of both an anti-CD3 and an anti-CD18 mAb, the initial
increase in [Ca2+] ; was as rapid as with crosslinking CD3 alone, but the increase
in [Ca2+ ] ; was prolonged (Fig . 1, A and C) . The average [Ca2+ ]i 7 min after adding
GaMIg was increased by 200 nM, compared with that observed after crosslinking
CD3 alone . This enhancement by crosslinking CD18 was observed only with con-
comitant crosslinking ofCD3, as crosslinking HLA-A,B,C with LFA-1 (Fig. 1, Band
D) or crosslinking CD4/CD8 with LFA-1 in appropriate clones (data not shown)
did not enhance the response and often decreased it .
The enhancement ofthe CD3 response could also be demonstrated using a mAb
directed to CDlla (LFA-lot) . Crosslinking CD11a alone with GaMIg did not change
the baseline [Ca2+ ] ; (data not shown) . However, as shown in Fig. 2, crosslinking
CD3 and CD11a prolonged the increase in [Ca2+ ] ;, whereas crosslinking HLA-A,B,C
and CD11a diminished the observed calcium response . 7 min after adding GaMIg,
the [Ca2+ ] ; of cells pretreated with both the anti-CD3 and anti-LFA-1 mAb was
-100 nM greater than that observed after crosslinking CD3 alone .
Fig . 3 shows that cloned T cells isolated from an individual who cannot make
a productiveß chain and thus cannot express LFA-1 (5) do not generate a prolonged
calcium signal after costimulation with anti-CD3 and anti-LFA-1 mAbs followed by
GaMIg. In addition, the response to crosslinking class I MHC molecules was not
modified by treatment with an anti-LFA-1 mAb . Thus, although the prolonged in-
crease in [Ca2+ ]i elicited by crosslinking CD3 and LFA-1 was small in magnitude,
it occurred reproducibly, was detected when either the ct or ß chain was crosslinked,
and required expression of LFA-1 .
CrosslinkingCD3 with LFA-1 Enhances the Proliferative Response ofHuman TCell Clones.
As crosslinking surface LFA-1 could prolong the calcium signal produced by cross-
FIGURE 2 .
￿
Crosslinking either
theaor the 0 chain ofthe LFA-1
molecule prolongs the [Ca2+] ;
response induced by anti-CD3
mAb . Clone NPl (CD4*) cells
were pretreated at 4°C with the
indicated mAb (anti-CD3-
OKT3 ; anti-CD18TS1/I8; anti-
CD11a-TSl/22) and washed.
Subsequent analysis was done
as described in Fig . 1 .436
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FIGURE 3 .
￿
Anti-LFA-1-induced prolongation ofthe
anti-CD3 calcium signal is not seen inT cell clones
from a child with LAD. Clone BRIO (CD4' ; <1%
LFA-l') cells isolated from achild with LAD were
pretreated at 4°Cwith the indicatedmAb(anti-CD3-
OKT3 ; anti-HLA-A,B,C-W6/32 ; anti-CD18-60.3),
washed, and analyzed as described in Fig. 1 .
linking CD3, the effect of crosslinking LFA-1 on the functional responses ofT cell
clones was examined . Table I shows the proliferative response of both aCD4+ and
aCD8+ clone . Treatment with an anti-CD18mAb with or without crosslinking sec-
ondary antibody did not affectDNA synthesis. TheCD4+ clone, but not the CD8+
clone responded somewhat to pretreatment with the anti-CD3 mAb alone, and this
response wasincreasedby crosslinking. Crosslinking both CD3 and CD18 markedly
enhanced [3H]thymidine incorporation in both the CD4+ and theCD8+ clone . As
previously observed (19, 21), crosslinking class I MHC determinants increased
[3H]thymidine incorporation . Crosslinking HLA-A,B,C andCD18, however, did not
change this response. As shown in Table II, crosslinking CD3 and CD11a also in-
creased [3H]thymidine incorporation compared with the response to either mAb
alone . The increase in [3H]thymidine incorporation was smaller than that seen in
theexperiment in Table I, demonstrating thevariation in the magnitudeof responses
of different clones . In addition, crosslinking a different anti-CD18 mAb (TSl/18)
TABLE I
Crosslinking CD3 and CD18 Enhances Proliferation ofHuman T Cell Clones
Clone LM2(CD4') or NP18 (CD8') was pretreated with saturating concentrations ofthe in-
dicated mAb (control-P1.17 ; anti-CD18-60 .3 ; anti-CD3-OKT3 ; anti-HLA-A,B,C-W6/32),
washed, andincubated for 36 h. 18 hbefore harvesting, 1 pCi of [3H]thymidinewas added .
All data are expressed as mean cpm t SEM.
Specificity of mAb
CD4'
Control
[3H]Thymidine
clone
+GaMIg
incorporation
CD8'
Control
clone
+GaMIg
cpm x 10-3 t SEM
Control 0 .6 t 0.0 0.5 ± 0.0 1 .4 f 0.1 1 .3 t 0.2
CD18 0.5 t 0.0 0 .6 t 0.0 1 .0 t 0.0 1 .6 ± 0.2
CD3 2.4 ± 0.1 8 .8 t 0.0 1.5 t 0.2 0.9 t 0.2
CD3+CD18 1 .4 t 0.1 44 .2 t 0.4 3 .0 t 0.3 22 .4 t 0.4
HLA-A,B,C 0.8 f0 .0 7.9t0.4 1.2t0 .0 16.8t0 .5
HLA-A,B,C +CD18 0.7 t 0.0 8 .4 t 0.1 0.9 t 0.0 11 .8 t 0.4WACHOLTZ ET AL.
TABLE II
Crosslinking Either the a or the,8 Chain of the LFA-1 Molecule
Enhances Proliferation of Anti-CD3-stimulated T Cell Clones
Clone NP7 (CD4') was pretreated with saturating concentrations of the indi-
cated mAb (control-P1 .17; anti-CD3-OKT3; anti-CD18-TS1/18; anti-CD1la-
TS1/22), washed, and incubated (105 cells/well) either with or without GaMIg.
Cells were cultured for 36 h. 18 h before harvesting, 1 pCi of [3H]thymidine
was added . All data are given as mean cpm t SEM.
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from that used in Table I (60.3) also enhanced proliferation ofanti-CD3-stimulated
clones. Thus, three different anti-LFA-1 mAbs enhanced the proliferative response
to anti-CD3 mAb.
Crosslinking CD3andEither CD18 or CD11aEnhances IL-2 Production.
￿
Theenhance-
ment of anti-CD3 mAb induced [3H]thymidine incorporation by the anti-LFA-1
mAb was apparent even when no additional exogenous IL-2 was added, suggesting
that IL-2 was being produced in these cultures. When IL-2 production wasdirectly
examined, as shown in Table III, crosslinking the surface LFA-1 molecule via either
the a or /3 chain or crosslinking CD3 alone resulted in little or no IL-2 production.
However, pretreating cells with both an anti-CD3 mAb and an anti-LFA-1 mAb
TABLE III
Crosslinking CD3 and CD18 or CD11a Increases IL-2 Production
ofAnti-CD3-stimulated T Cell Clones
Clone (NPI ; CD4') or clone 2 (LM5; CD4') was pretreated with the indicated
rnAb (control-P1 .17; anti-CD18t-60.3; anti-CD182-TSl/18; anti-CD1la-TSl/22;
anti-CD3-OKT3), washed, and incubated (105 cells/well) with or without GaMIg.
Supernatants were harvested at 18 h and assayed for IL-2 production.
Specificity
of mAb
Clone 1
Control +
IL-2 production
Clone 2
GaMIg Control + GaMIg
U1106 cells
Control 0.0 0.0 0.0 0.0
CD18' 0 .0 0.0 0.0 0.0
CD182 0.0 0.0 0.0 0.0
CD11a 0.0 0.0 0.0 0.0
CD3 1 .0 0.0 0.0 0.6
CD3 + CD18' 0.3 4.2 0.0 9.6
CD3 + CD182 0.6 5.8 0.0 9.6
CD3 + CD11a 0.6 4.8 0.3 8 .3
Specificity
of rnAb
[3H]Thymidine incorporation
Control + GaMIg
cpm x 10-3 t SEM
Control 1 .6 t 0.1 1 .4 t 0.1
CD3 1 .6 t 0.1 1 .2 t 0.1
CD18 1 .3 t 0.2 1 .3 t 0.2
CDlla 1 .6 f 0.1 1 .7 t 0.0
CD3 + CD18 2.1 t 0.0 5.2 t 0.6
CD3 + CDila 2.3 t 0.1 8 .1 t 0.3438
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markedly increasedIL-2 production. The enhancement couldbe demonstrated using
mAbs directed at either the a chain (anti-CD18) or the ci chain (CD11a), and the
magnitude of increase was comparable. Table IV demonstrates that the enhance-
ment of IL-2 production by crosslinking CD3 and LFA-1 does not occur in cells
isolated from an individual with LAD, although crosslinking class I MHC mole-
cules did stimulate IL-2 release. Thus, the LFA-1-mediated enhancement of IL-2
production requires costimulation of CD3, can be induced by crosslinking either
the a or R chain, and requires LFA-1 surface expression.
Crosslinking LFA-1 to LFA-1 Enhances the Functional Response to CD3, but not to HLA-
A,B,C. To determinewhethercrosslinking LFA-1 to LFA-1 was sufficient to increase
the response to CD3 or whether crosslinking CD3 to LFA-1 was necessary, experi-
ments using isotype-specific crosslinking secondary antibodies were carried out. Fig.
4 demonstrates the typical responses observed using three different clones. In the
first clone, NP18 (CD8 +), the IgG1 anti-CD3 mAb elicited some IL-2 production
whethercrosslinking antibody was added or not. IL-2 production by theIgG2aanti-
CD3 mAb was seen when anti-IgG2a crosslinking antibody was added. No IL-2
production resulted from pretreatment and crosslinking with either oftwo anti-CD18
mAbs. When cellswere pretreated with both an anti-CD3 and either of thetwo anti-
CD18 mAbs, the usual enhancement of IL-2 production was observed after cross-
linking by GaMIg. When surface LFA-1 was specifically crosslinked on cells also
carrying an anti-CD3 mAb of a different isotype, IL-2 production was significantly
greater than that produced when either CD3 or LFA-1 was crosslinked on cells
pretreated with a single mAb. This was observed regardless of whether the anti-
LFA-1 mAb was of the IgGI or IgG2a isotype. Crosslinking the anti-CD3 mAb of
the IgG2a isotype on cells stainedwith both an IgG2a anti-CD3 mAb and the IgG1
anti-CD18 mAb also increased IL-2 production above the level induced by cross-
linking CD3 alone, suggesting that the presence of an anti-LFA-1 mAb, although
TABLE IV
Anti-LFA-1 Does not Increase IL-2 Produced by Anti-M-stimulated
T Cell Clones Deficient in the Expression of LFA-1
Clone LAD 1 (BR2 ; CD4') and clone LAD 2 (BR4; CD4*), which do not express detectable
surface LFA-1, and clone NP1 (CD4', LFA-1') were pretreated with the indicated rnAb
(control-P1 .17; anti-CD3-OKT3; anti-CD18-60 .3; anti-HLA-A,B,C-W6/32), washed, and in-
cubated (105 cells/well) with or without GaMIg. Supernatants were harvested at 18 h and as-
sayed for IL-2 production.
Specificity of rnAb NIL
LAD 1
+ GaMIg
IL-2 production
LAD 2
NIL + GaMIg NIL
NPl
+ GaMIg
U1106 cells
Control 0.0 0 .0 0.0 0 .0 0.0 0 .0
CD3 0.0 1 .0 0.0 1 .0 0.0 0.0
CD18 0.0 0 .0 0.0 0 .0 0.0 0 .0
CD3 + CD18 0.0 1 .0 0 .0 1 .0 0.0 4.0
HLA-A,B,C 0.0 7 .2 0.0 6 .0 0.0 6 .4
HLA-A,B,C + CD18 0.0 6.8 0.0 6.4 0.0 3 .6WACHOLTZ ET AL.
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FIGURE 4.
￿
Specifically crosslinking LFA-1
to LFA-1 augments thefunctional response
of anti-CD3-stimulated clones. Clones
NP18 (CD8'), LM5 (CD4+), or LM2
(CD4') were pretreated with saturating
concentrations oftheindicated mAb(con-
trol-P1.17 [IgG2a], MOPC [IgGl] ; an-
ti-CD3-Leu-4 [IgG1], OKT3 [IgG2a];
anti-CD18TS1/IS [IgGl], 60.3 [IgG2a];
anti-CDllaTS1/22 [IgGl]; anti-HLA-
A,B,C-MB40.5 [IgGl]), washed andincu-
bated(105cells/well) with isotype-specific
anti-IgGI or anti-IgG2a secondary anti-
bodies or GaMIg. When anti-IgGI oranti-
IgG2a isotype-specific antibodies were
used to crosslink, P1.17 (IgG2a)or MOPC
(IgGI),respectively, were addedto thecul-
tures to prevent nonspecific crosslinking.
Supernatants were harvested at 18 h and
assayed for IL-2 production as described
in Materials and Methods.
not crosslinkedwith asecondary antibody, mightreciprocallyenhancethe anti-CD3
response.
The second experiment using clone LM5 showed that crosslinking the a chain
(CD11a) when cellswere pretreated withan anti-CD3 mAb and an anti-CD11amAb
increased IL-2 production, although the amount produced wassmallcompared with
crosslinking via CD18 in clone NP18. In the final experiment with clone LM2, the
response to crosslinking CD18 by cells that were also pretreated with an anti-CD3
mAb was again increased overthe response to crosslinking either CD3 or CD18 on
cellspretreated with either mAb alone. In addition, when cells were pretreated with
an anti-HLA-A,B,C mAb, crosslinking with either the isotype-specific antibodies
orGaMIg stimulated IL-2 production. However, pretreatment ofcells with an anti-
CD18 mAb inaddition to an anti-HLA-A,B,C mAb not onlydid not stimulate IL-2
production when only CD18 was crosslinked, but also somewhat decreased IL-2
productionwhen HLA-A,B,C was crosslinked either usingthe isotype-specific anti-
body orGaMIg. In allofthese experiments, the amount ofIL-2 generated bycross-
linking LFA-1 on cells pretreated with both an anti-CD3 and an anti-LFA-1 mAb
was atleast as greatthat generated byrandom crosslinking using GaMIg. It should
benoted that in these experiments, excess control mAb ofthe alternate isotype was
added to the cultures to eliminate any isotype-nonspecific crosslinking. Moreover,
a high degree ofspecificity was observed in that IL-2 production was elicited only
bythe crosslinking antibody ofthe correct isotype. Thus, although theclones varied
in their abilityto respond to the stimuli provided, crosslinking LFA-1 alone on cells440
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carrying both an anti-CM mAb andan anti-LFA-1 mAbconsistently enhanced IL-2
production above that observed by crosslinking either surface proteinon cells treated
with a single mAb.
Specifically Crosslinking LFA-r Increases[Ca'-'], if CellsAre Pretreated with Both an Anti-
CD3 andan Anti-LFA-1 mAb. The previous experiments with isotype-specific cross-
linking suggested that crosslinking LFA-1 could transmit an independent signal to
the T cell. This was confirmed by measuring the change in [Ca2']i generated by
isotype-specific crosslinking of individual surface proteins as shown in Fig. 5. As
seen previously, crosslinking LFA-1 via either the a or the (3 chain with either the
isotype-specific antibody or GaMIg on cells pretreated only with theanti-LFA-1 mAb
did not increase [Ca2'];. However, when cells were pretreated with both an anti-
CD3 and an anti-CD18 mAb, followed by specific crosslinking ofonly the anti-LFA-
1 mAb, a delayed, but sustained increase in [Ca2']i by 30-70% of T cells was ob-
served. In Fig. 5 A, the delayed response that occurred after crosslinking only CD18
when cells were also pretreated with an anti-CM mAbwascompared with therapid
response elicited by crosslinking only the anti-CM mAbwith the appropriateisotype-
specific antibody. The lack of an immediate increase in [Ca2'], when CD18 was
crosslinked on cellsalso reactedwith an anti-CD3 mAb demonstrates the specificity
of the isotype-specific secondary antibody. Fig. 5 B shows that increasing [Ca2'],
by crosslinking LFA-1 using and anti-CD18 mAb of adifferent isotype also required
pretreating the cellswith an anti-CM mAb. In,addition, GaMIg-induced aggrega-
tion was compared with isotype-specific crosslinking. GaMIg-induced crosslinking
of CD3 and CD18 resulted in an increased and more sustained signal . In Fig. 5 C,
crosslinking either the a chain (CD11a) or thea chain (CD18) of LFA-1 when cells
were also reacted with an anti-CD3 mAb was shown to be equally effective in in-
creasing [Ca2']i. Fig. 5 C also shows that specifically crosslinking CD3 on cells
pretreated with both mAbs resulted in a more sustained increase in [Ca211, than
crosslinking CD3 on cells reacted with an anti-CM mAb alone. These results indi-
cate that enhancement of the increase in [Ca2+]i resulted from independently cross-
Time (min)
FtGURB 5.
￿
Crosslinking LEA-1 to LFA-1 when cells are also pretreated with an anti-CD3 rnAb
results in increased [Ca2'];. (A) Clone NPl (CD4') was pretreated with the following rnAb: anti-
CD3-OKT3 (IgG2a); anti-CD18TSl/18 (IgGl). (B) Clone NP18 (CD8') was pretreated with the
following rnAb: anti-CD3-158.86 (IgG2b); anti-CD18-60.3 (IgG2a). (C) Clone NP13 (CD8') was
pretreated with the following rnAb: anti-CD3-OKT3 (IgG2a): anti-CD18TS1/18 (IgGl); anti-
CDl1aTS1/22 (IgGl). After washing, cells were analyzed as described in Fig. 1. Crosslinking
by the appropriate isotype-specific secondary antibodies is indicated by brackets. Crosslinking
by GaMIg (B) is indicated by parentheses.WACHOLTZ ET AL .
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linkingeitherCD3 orCD11a/CD18 on cellsreacted withmAbs to both determinants
and did not require purposeful crosslinking of these structures . Thus, it was not
necessary to aggregateCD3 to LFA-1 directly to generate andtransmit an activation
signal to the T cell clones .
The Enhancement of Signaling by the Combination ofmAbs to LFA-1 and CD3 Requires
Intact, Bivalent Anti-CD3 mAb. As shown above, crosslinking the LFA-1 molecule
transmitted an activation signal to the cell if an anti-CD3 mAb was also bound to
the cell . To determine whether bivalent anti-CD3 mAb was required or whether
binding by a Fab fragment of an anti-CD3 mAb was sufficient, both the change
in [Ca2+ ]i and IL-2 production were examined . Fig . 6 shows that when cells were
pretreated with an Fab fragment of an anti-CD3 mAb, a typical rapid increase in
[Ca2+ ]i occurred after crosslinking with GaMIg. Moreover, when cells were pre-
treated with both an anti-CD3 Fab fragment and either an anti-CD18 or an anti-
CD11a mAb followed by crosslinking with GaMIg, a more sustained increase in
[Ca2+ ]; was seen similar to the pattern observed when CD3 and LFA-1 were cross-
linked using a bivalent anti-CD3 mAb. However, when cells were pretreated with
both the Fab fragment of an anti-CD3 mAb and an anti-CD18 mAb (Fig. 6A) or
an anti-CD11a mAb (Fig . 6B) followed by crosslinking with an isotype-specific sec-
ondary antibody to crosslink only the LFA-1 molecule, no enhanced signal was ob-
served .
When IL-2 production was examined (Table V), similar results were observed .
Thus, neithertheFabfragment oftheanti-CD3 mAb, norcrosslinking LFA-1 alone,
resulted in IL-2 production, whereas crosslinking the Fab fragment ofthe anti-CD3
mAb with either an isotype-specific secondary antibody or GaMIg induced IL-2
production . However, specifically crosslinking the LFA-1 molecule when cells were
FIGURE 6 .
￿
Crosslinking LFA-1 specifically when cells are also pretreated with a univalent anti-
CD3mAb Fabdoes not increase [Ca2+] ; . (A)Clone NP19 (CD4*) was pretreated with the fol-
lowing mAb : (a-CD3 Fab-64 .1, IgG2a ; a-CD18TSl/18, IgGl). (B) Clone NP13 (CD8*) was
pretreatedwith the followingmAb : (a-CD3 Fab-64.1, IgG2a; a-CDllaTS1/22, IgGl). The brackets
or parentheses indicate the surface antigen that wasbeingcrosslinked . Crosslinking ofthea-CD3
Fab aloneandthea-CD3Fab+ a-CDl8/a-CDlla wasaccomplished withGaMIg. Specific cross-
linking ofa-CD18/CDl1a when cells also were reacted with the a-CD3 Fabwas done with the
anti-IgG1 isotype-specific antibody .442
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TABLE V
Crosslinking LFA-1 Increases IL-2 Production When CD3 is
Bound by Bivalent Anti-CD3 mAb
Clone NP18 (CD8') was pretreated with the indicated rnAb (control-P1 .17
or MOPC; anti-CD3(Fab)-64.1, IgG2a; anti-CDlla-TS1/22, IgGl), washed,
and incubated (105 cells/well) with or without the indicated crosslinking anti-
body. When cells were incubated with an anti-IgG anti-IgGI or an anti-IgG2a
antibody, control rnAb ofthe alternate isotype (P1 .17-IgG2a or MOPC-IgGl,
respectively) were added to block potential crossreactivity. Supernatants were
harvested at 18 h and assayed for IL-2 production .
' Specificity of crosslinking antibody.
also reacted with the Fab fragment of the anti-CD3 mAb failed to increase IL-2
production, whereas crosslinking the Fab fragment of the anti-CD3 mAb on cells
also reacted with anti-LFA-1 mAb resulted in marked inhancement of IL-2 produc-
tion. These experiments suggest that intact bivalent anti-CD3 mAb must be bound
on the cell surface in orderfor crosslinking of LFA-1 to transmit an activation signal
to the cell.
Discussion
The LFA-1 molecule has a well-established role in mediating the adhesion or in-
teraction of T cells and a variety of other cell types (1, 5, 6). By using human T
cell clones that can be activated by crosslinking particular surface antigens in the
absence of T cell-accessory cell or Tcell-solid phase interactions, these studies have
shownthat LFA-1 can actas asignalingmolecule as well. The costimulation of CD3-
induced responses required expression o£ the LFA-1 molecule, and, therefore, could
not be explained by unanticipated crossreactivity of the mAb. Thus, T cells cloned
from a child with LAD and no detectable surface ot or 0 chain did not exhibit the
prolongation of the anti-CD3-induced calcium signal or the enhancement of anti-
CD3-stimulated IL-2 production. The lack of a requirement for cellular interac-
tions in the generation of activation signals by crosslinking LFA-1 was confirmed
during the measurement of [Ca2+]i by flow cytometry. Not only are the cells in di-
lute suspension and constantly being stirred, but only single cells, not doublets or
aggregates, were analyzed in the flow cytometer.
Study of the change in [Ca2+]i first suggested that crosslinking LFA-1 molecules
delivers direct signals to the T cells. The change in [Ca2+]; is important because
an increase in [Ca2+]; is one of the critical early biochemical changes in T cell acti-
vation (22). Moreover, a change in [Ca211i demonstrates that transmembrane sig-
Specificity of rnAb Control'
IL-2
IgG1-
U1106
production
IgG2a'
cells
Ig'
Control 0.0 0 .0 0 .0 0.0
CD3(Fab) 0.0 0 .0 14.5 2 .0
CD11a 0.0 0.0 0.0 0 .0
CD3(Fab) + CDlla 0.1 0 .0 26 .8 44.7WACHOLTZ ET AL.
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naling has occurred. Crosslinking LFA-1 viaeither the aor thea chainusingGaMIg
or an isotype-specific secondary antibody induced little or no change in [Ca2+]i in
cells reacted with only a single mAb. This is consistent with our previous results
(19) and those of others (23) using freshly prepared human peripheral T lympho-
cytes, but different from anotherstudy in which a small increase in [Ca2+]i was ob-
served after crosslinking (24). The cells used in that report were not purified, how-
ever, and the minimal increase in [Ca2+]i was limited to a small percentage of cells.
Therefore, it was possible that anti-LFA-1 mAb directly induced an increase in
[Ca2+]i in cells other than T cells.
Although mAbs to LFA-1 did not induce a change in [Ca2+]i alone, they did alter
thecalcium response induced by anti-CD3 mAb. Thus, when clones were pretreated
with an anti-CD3 mAb and either an anti-CD18 or CD11a mAb followed by cross-
linking, a prolongation ofthe anti-CD3-induced elevation in [Ca2+]i was observed.
This increase, though small, was consistently observed in the different clones and
was detected whether LFA-1 was crosslinked via the a or /3 chain. This augmenta-
tion was limited to CD3 as crosslinking LFA-1 and HLA-A,B,C or CD4/CD8 (data
not shown) diminished the typical delayed, sustained calcium response seen after
crosslinking these surface antigens. The costimulation via LFA-1 is different from
that observed with mAbs to other surface molecules that are co-mitogenic for anti-
CD3-stimulated cells. Thus, mAb to HLA-A,B,C, CD2, CD4/CD8, CD5, or CD28
can induce readily detectable increases in [Ca2+ ]i when crosslinked alone on cells
not reacted with an anti-CD3 mAb (13, 19, 24, 25), whereas mAbs to LFA-1 do not.
These results indicate that the ability of a mAb that recognizes a surface antigen
to costimulate with anti-CD3 is not predicted by its ability to induce a change in
[Ca"ji alone.
Crosslinking CD3 with LFA-1 not only prolonged the increase in [Ca2+]i but also
augmented T cell activation as measured by [3H]thymidine incorporation or IL-2
production. The enhancement of responses induced by crosslinking LFA-1 did not
occurwith allmodesofstimulation as concomitant crosslinking ofHLA-A,B,C with
LFA-1 did notaffect or somewhat diminished the response to crosslinking HLA-A,B,C
alone. Thereis no clearexplanation for thedifference between theresponse induced
by thecombination ofanti-CD3 + LFA-1 and that from anti-HLA-A,B,C + LFA-1,
although the results suggest that stimulation by the CD3/TCR molecular complex
might be uniquely costimulated by engagement of LFA-1 molecules. Thus, costimu-
lation viaLFA-1 may be of special importance during the accessorycell-T cell inter-
action involved in antigen presentation.
Because activation by LFA-1 could only be demonstrated when CD3 was engaged,
the relationship between crosslinking CD3 and LFA-1 was further examined by
specifically crosslinking one or the other surface antigen with isotype-specific sec-
ondary antibodies when cells were pretreated with two mAbs of different isotypes.
It was important in theseexperiments that the isotype-specific crosslinking antibodies
did not nonspecifically bind mAbs of another isotype. In our experiments, a high
degree ofisotype specificity waspresent in that IL-2 production in cells reacted with
a single mAb was elicted only by crosslinking antibody of the correct isotype, even
when control mAb of the alternate isotype normally added in excess was not added444
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to the cultures. In addition, the isotype-specific antibodies increased [Ca2+]; when
the surface mAb was of the correct isotype, but not when cells were stained with
mAbs of adifferent isotypein control experiments (datanotshown). Thus, no cross-
reactivity was detected at the level ofsensitivity ofthetechniques used. The isotype-
specific crosslinking experiments demonstrated that it was not necessary to directly
crosslink CD3 to LFA-1 to generate an activation signal. Although crosslinking cells
reacted with the anti-LFA-1 mAb alone did not stimulate the cells or increase
[Ca2+];, crosslinking LFA-1 when the cells carried an anti-CD3 mAb that was not
further crosslinked was a strong stimulus for IL-2 production and increasing
[Ca2']i. Of note, the stimulation of IL-2 production by independently crosslinking
LFA-1 on cells pretreated with both an anti-CD3 and an anti-LFA-1 mAb was at
least as effective as aggregating CD3 + LFA-1 by crosslinking with GaMIg. How-
ever, univalent bindingof the CD3 complex by an anti-CD3 Fab fragment was not
sufficient to augment the LFA-1 signal. Therequirementforbivalent anti-CD3 mAb
indicates that some aggregation of CD3 molecules is necessary for costimulation.
Although our data are the most direct demonstration of signaling via the LFA-1
molecule, other work has been consistent with such a role for this surface antigen.
AmAbthat recognized the achainofmouse LFA-1 stimulated proliferation ofCTL
clones without additional crosslinking of this IgM mAb (26). However, this mAb
coprecipitated proteins in addition to the LFA-1 a subunit so that the stimulatory
effect could not be definitely ascribed to its bindingof the LFA-1 molecule. The ob-
servation that immobolized anti-LFA-1 mAb could stimulateperipheral bloodTcells
ifPMA waspresentsuggestedthat immobilized anti-LFA-1 mAb triggeredcostimula-
tory increases in [Ca"]; (10). However, the current findings that mAbs to LFA-1
failed to induce measurable increases in [Ca"]i, even if crosslinked, question that
conclusion. Our results also differ somewhat from those of van Noesel et al. (12),
who found that soluble anti-CD18 mAbs were inhibitory of immobilized anti-CD3-
induced proliferation, whereas soluble anti-CDlla mAbs increased responses. We
have previously been unable to show inhibition of immobilized anti-CD3-induced
proliferation by soluble anti-CD18 mAbs (9). Moreover, the findings of van Noesel
et al. (12) are difficult to reconcile with the current results that clearly demonstrate
that augmentation of anti-CD3-induced T cell activation canoccurwhen either anti-
CD18 or anti-CD11a mAb is used as a costimulant. No major differences in the sig-
naling potential of the a or (3 chains of the LFA-1 molecule could be documented.
Thus, although previous work has suggestedthat LFA-1 mighthave asignaling role,
consistent results to support this possibility have not emerged. The current experi-
ments usingTcell clones avoided some ofthe pitfalls ofprevious studies and clearly
demonstrated a costimulatory role for LFA-1 in anti-CD3-activated T cells.
Perturbation of other molecules of the integrin family may also result in signal
transduction. Thus, for example, epinephrine-induced stimulation of the Na''/H+
antiporter in platelets was found to be dependent upon fibrinogen binding of the
integrin glycoprotein IIb-IIIa (27), andbindingof gp IIb-IIIa resulted in cytoskeletal
association of the protein (28, 29). In 3T3 cells, fibronectin binding to a fibronectin
receptor resulted in differential expression of a number of genes (30). In addition,
a mAb that recognized CD11b (Mac-1) has been noted to provide a costimulatory
signal for macrophage activation (31). Although these experiments aremore indirectWACHOLTZ ET AL.
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than those of thepresent study, they supportthe possibility that signal transduction
is a more general property of the integrin family of molecules.
Associationwith thecytoskeleton maybe an importantmechanismby whichLFA-1
or other integrin molecules can participate in cellular activation. Cytoskeletal com-
ponentslocalize in areas of cell contact when integrin family molecules are engaged
(1, 32, 33). In addition, a plasma membrane fibronectin receptor, the cell-substrate
attachment antigen, physically binds a cytoskeletal component, talin (34). Cross-
linking of LFA-1 on murine T cells is claimed to cause redistribution of talin, but
not other cytoskeletal proteins if the cells are also treated with phorbol esters (35).
Theseresults, although preliminary, suggest that thereceptor-ligand bindingofintegrin
family molecules may result in establishment of a bridge to the cytoskeleton that
may be important in cellular activation.
Additional evidence that the integrin molecules may be involved in signal trans-
duction derives from studies of protein phosphorylation. Thus, the a chain of the
LFA-1 molecule is constitutively phosphorylated and (3 chain phosphorylation can
be inducedby PMA (36). Moreover, thecell-substrate attachment antigen sequence
has been determined and contains a tyrosine residue in a region homologous with
the phosphorylation site of epidermal growth factor, suggesting that tyrosine phos-
phorylation of this molecule may be important in regulating its function (37). The
data thus suggest thepossibility that LFA-1 and other integrin molecules canbe phos-
phorylated and can associate with the cytoskeleton. Either or both of these mecha-
nisms may be important in their capacity to function as signaling molecules.
These studiesdemonstrate cooperativitybetween the signal-transducing capabili-
ties of CD3 and LFA-1. Independently crosslinking LFA-1 generates an activation
signal for the cell, but only when CD3 is also engaged by a bivalent mAb. There
areanumber of potentialexplanations forthis finding, including thepossibility that
there is no functional or physical interaction between the two molecules, but that
the signals generated independentlysynergizein activating thecell. Since it is difficult
to show any signaling capability of LFA-1 alone, this does not appear to be likely.
Alternatively, engagement of oneofthe molecules might lead to enhanced signaling
capability of the other and thereby lead to an enhanced functional reponse. One
potential mechanism for the latter phenomenon could be through cytoskeletal reor-
ganization, as binding ofeither the CD3/TCR or LFA-1 is associated with directed
movement of a number of components of the cytoskeleton (35, 38). Although the
details of these rearrangements are not known, it is possible that movement of
cytoskeletal proteins triggered by crosslinking of one of these surface determinants
could result in an organization of the other molecule that is more conducive to sig-
naling. Both CD3 and LFA-1 also undergo phosphorylation ofcytoplasmic sequences
(36, 39). Thus, activation of protein kinases, including protein kinase C or A, by
engagement of these surfaceantigens couldbe used to communicateapositive influence
to other signaling molecules in the cell membrane. Either or both of these events
could result in cooperativity between CD3- and LFA-1-induced transmembrane sig-
naling. In this regard, it is tempting to speculate that binding of T cells and APC
viaLFA-1-ICAM interactions mightlead to enhanced signalingthrough the CD3/TCR
complex when antigen is recognized. Thus, interaction with LFA-1 under physio-
logical circumstances may notonly facilitate cellular adhesion, butin doing so, may
deliver important costimulatory signals to amplify T cell activation.446
￿
SIGNALING VIA LEUKOCYTE FUNCTION-ASSOCIATED ANTIGEN 1
Summary
The leukocyte function-associated antigen 1 (LFA-1) molecule is well established
as a surface protein involved in cellular adhesion and interaction, but therehas been
little information about whether engagement ofthis molecule can also directly modify
cellular activation. These studies demonstrate that crosslinking the LFA-1 molecule
on human T cell clones transmits a unique signal to the cell. Crosslinking LFA-1
alone did not increase intracellular calcium ([Ca2+]i), nor did crosslinking LFA-1
activate the cells as measured by IL-2 production or [3H]thymidine incorporation.
However, when CD3 and LFA-1 were crosslinked, a more prolonged calcium signal
was observed than when CD3 alone was crosslinked. Moreover, IL-2 production
and DNA synthesis were greatly augmented. These responses could be demonstrated
when LFA-1 was crosslinked via either the a or the /3 chain, and required surface
expression of the LFA-1 molecule as no enhancement was observed in T cell clones
from a child with leukocyte adhesion deficiency. The enhancement of cellular acti-
vation by LFA-1 did not require that it be directly crosslinked to the CD3 complex.
Thus, crosslinking LFA-1 alone with isotype-specific secondary antibodies on cells
also pretreated with an anti-CD3 mAb of a different Ig isotype stimulated the cells
as effectively as crosslinking both surface antigens with GaMIg. Similarly, a delayed,
but sustained increase in [Ca2+]i was elicited. This increase in [Ca2+]i and the en-
hanced functional responses required engagement of CD3 with an intact bivalent
anti-CD3 mAb, as crosslinking LFA-1 on cells also reacted with Fab fragments of
an anti-CD3 mAb did not increase [Ca2+]i, nor activate the cells. These data indi-
cate that LFA-1 can convey activation signals to T cells. Synergism in signaling can
be observed upon crosslinking of LFA-1 and independently crosslinking CD3. In
the physiologic interaction between T cells and accessory cells, the interaction of
LFA-1 with its ligand, intercellular adhesion molecule 1, may therefore not only facili-
tate cellular adhesion, but also may amplify T cell activation by delivering costimulatory
signals.
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technical assistance, and Lisa Wicktor for her help in the flow cytometric studies.
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